The growth in the digital pathology market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, and growing applications of digital pathology in drug development and companion diagnostics. On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent.
Projected Revenue Surge Globally:
The Global Digital Pathology market is projected to reach USD 1,371 million by 2026 from USD 736 million in 2021, at a CAGR of 13.2% during the forecast period.
The scanners segment accounted for the largest share of the Digital Pathology market in 2020.
Based on products, the digital pathology market has been segmented into scanners, software, and storage systems. The large share of the scanners segment can be attributed to the high price of scanners and the increasing adoption of digital pathology solutions.
The human pathology segment accounted for the largest share of the Digital Pathology market in 2020
Based on type, the global digital pathology market is segmented into human pathology and veterinary pathology. The human pathology segment accounted for the largest share of the digital pathology market in 2020. This is due to the increasing number of cancer research activities and growing collaborations among research institutes, universities, and pathology laboratories.
The drug discovery, segment accounted for the largest share of the Digital Pathology market in 2020.
Based on application, the digital pathology market is segmented into drug discovery, disease diagnosis, and training & education. The drug discovery segment accounted for the largest share of the digital pathology market in 2020. Growth in R&D expenditure fuelled by the need for numerous preclinical and clinical studies performed during the drug discovery and development process is a major factor responsible for market growth.
End Users:
The pharmaceutical & biotechnology companies, segment accounted for the largest share of the Digital Pathology market in 2020.
Based on end users, the global digital pathology market is segmented into pharmaceutical & biotechnology companies, hospitals & reference laboratories, and academic & research institutes. The pharmaceutical & biotechnology companies segment accounted for the largest share of the digital pathology market in 2020. The large share of this segment can be attributed to the increasing use of digital pathology for drug discovery studies and drug toxicology testing. Biotechnology companies also use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.
Geographical Growth Dynamics:
The market in North America is projected to witness the highest growth rate during the forecast period (2021–2026).
North America accounted for the largest share of the digital pathology market in 2020. The increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favourable reimbursement policies, and the implementation of favourable initiatives by the governments in the US and Canada are major factors driving the growth of the digital pathology market in North America.
The major players in the global Digital Pathology market include Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Aiforia Technologies Oy (Finland), Akoya Biosciences (US), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (US), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Inspirata, Inc. (US), PathAI (US), Proscia Inc. (US), Kanteron Systems (Spain), Mikroscan Technologies (US), Motic (US), and Paige (US).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
